A quantitative analysis demonstrated that the ratio of IGFBP-3 to β-actin was significantly increased in AD brains in comparison to non-AD controls (n = 5, 188.1 ± 23.9 %, p < 0.05; Fig. 2b). This evidence concerns the gene IGFBP3 and Alzheimer disease.